NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-EB-19-002 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support full development of entirely new or next generation noninvasive human brain imaging tools and methods that will lead to transformative advances in our understanding of the human brain. The FOA seeks innovative applications that are ready for full-scale development of breakthrough technologies with the intention of delivering working tools. This FOA represents the second stage of the tool/technology development effort that started with RFA-MH-14-217 and RFA-MH-15-200
Notice NOT-AT-19-030 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-20-300 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the development or application of advanced computational and statistical tools to integrate brain tissue and single-cell genomic data in order to advance our understanding of the cell type-specific gene regulatory networks and biological pathways involved in the pathogenesis and pathophysiology of mental disorders.
Funding Opportunity RFA-AG-20-041 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites early stage innovative and exploratory research focusing on understanding the regulation of brain regional and cell type-specific protein dynamics in Alzheimer's disease (AD). In particular, this FOA seeks applications proposing to develop novel proteomic platforms and animal models to further understanding of the alteration of a single-cell neuronal cell proteome in the central nervous system (CNS) during the course of aging and AD.
Funding Opportunity RFA-AG-20-042 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the regulation of brain regional and cell- type- specific proteome dynamics in Alzheimers disease (AD).
Funding Opportunity RFA-AG-20-028 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research involving pragmatic clinical trials on dissemination and implementation of practical approaches to hypertension treatment and control strategies among older adults with multimorbidity in order to prevent sequelae, including mild cognitive impairment and dementia.
Funding Opportunity RFA-AG-20-018 from the NIH Guide for Grants and Contracts. The goal of the GEMSSTAR program is to provide support for early-career physician-scientists trained in medical or surgical specialties or early-career dentist-scientists to launch careers as future leaders in aging- or geriatric-focused research. To achieve this goal, the GEMSSTAR Funding Opportunity Announcement (FOA) provides small grants to conduct transdisciplinary aging research that will yield pilot data and experience for subsequent aging research projects.
Funding Opportunity RFA-DA-20-008 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.
Funding Opportunity RFA-DA-20-009 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.
Notice NOT-MH-19-036 from the NIH Guide for Grants and Contracts
Notice NOT-GM-19-045 from the NIH Guide for Grants and Contracts
Notice NOT-HD-19-017 from the NIH Guide for Grants and Contracts
Notice NOT-HD-19-018 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-20-150 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications to create a Marmoset Coordination Center. The awardee will be responsible for two separate but related activities. The first activity will be to become the repository for genomic, pedigree, and event records (date of birth, medical, reproductive history) for captive marmosets. The awardee is expected to use that information to help make breeding recommendations to maximize the health and genetic diversity of the marmosets in primate colonies. Applicants are encouraged to adopt the model used by the Association of Zoos and Aquariums.
Funding Opportunity RFA-MH-20-145 from the NIH Guide for Grants and Contracts. The common marmoset has recently emerged as a promising model system to understand the primate brain. In particular, marmoset behavior is similar in many ways to human behavior and the technology for germ line transmission of exogenous genetic information is now possible. However, existing colonies and commercial sources are currently unable to provide sufficient marmosets for neuroscience research.
Funding Opportunity PAR-19-304 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phase II (R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging or multiple chronic conditions in older people (e.g., sarcopenia, hearth failure with preserved ejection fraction (HFePF), immunosenescence, pulmonary fibrosis, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasisand autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. Applications submitted in response to this FOA may involve novel treatment targets and/or innovative approaches for engaging known targets.
Funding Opportunity PAR-19-305 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R21/R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging and/or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasisand autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs.
Funding Opportunity RFA-DA-20-015 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support the development of Clinical Outcome Assessments (COAs) for Substance Use Disorders (SUDs) aiming to be qualified by the Food and Drug Administration (FDA) as Drug Development Tools (DDTs).The FDA qualification of a COA is based on a review of the evidence to support the conclusion that the COA is a "well-defined and reliable assessment of a targeted concept(s) in a specified context of use in adequate and well-controlled investigations". Once qualified as a DDT, the COA will become a publicly available instrument and can be deployed within a specified context of use (COU) as a sensitive, reliable and validated instrument. COA can be a patient-reported outcome (PRO), a clinician-reported outcome (ClinRO), an observer-reported outcome (ObsRO) or a performance outcome (PerfO). Applications may focus on the creation and development of a new COA, or on modification/optimization of an existing COA. The final goal is to have FDA-qualified COA(s) measure(s) that would be acceptable to regulatory authorities when used in SUDs clinical trials. It is expected that such FDA-qualified COAs will have a potential to catalyze the regulatory approval path for new treatments.
Notice NOT-HL-19-710 from the NIH Guide for Grants and Contracts
Notice NOT-HL-19-703 from the NIH Guide for Grants and Contracts